UF Breakthrough Could Reshape RNA Editing With World’s First DNA-Guided CRISPR (UF News)
UF researchers developed a new form of CRISPR technology that could make diagnostics and treatments safer, more precise and more affordable, while opening the door to entirely new ways of controlling disease.
iOncologi Secures Foundational U.S. Patent As Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival With Cancer Immunotherapy (Bio Space))
UF startup iOncologi, Inc. announced that USPTO has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.
Targeting RNA
Disney and his team at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida, have discovered more than 200 unique RNA-targeting compounds. His methods and discoveries have changed minds, igniting a global race to treat incurable diseases via their RNA.
UF Researchers’ Genetic Detection Discovery Has Implications for Medical Diagnostic Testing
University of Florida researchers have found a new use for “genetic scissors” to detect RNA, a discovery that could lead to faster, more accurate and less expensive diagnostic tests for a host of diseases.
Genetic Cause of Als and Dementia Repaired by RNA-Targeting Strategy Developed at UF Scripps
Scientists at UF Scripps Biomedical Research have developed a potential medicine for a leading cause of ALS and dementia that works by eliminating disease-causing segments of RNA. The compound restored the health of neurons in the lab and rescued mice with the disease.
UF Scripps Researcher’s Drug-Discovery Method Shows Promise Against Aggressive Breast Cancer
UF Scripps Biomedical Research scientist Matthew Disney, Ph.D. has found yet another groundbreaking approach to a problem that has long vexed scientists: How to cure diseases by targeting key RNA. Until now, RNA has been an elusive target for drug discovery. Discoveries made by Disney and his collaborators have rewritten that dogma.